MUMBAI (Reuters) - Sun Pharmaceutical Industries (SUN.NS) reported a 46.5 percent drop in quarterly net profit after it set aside 5.84 billion rupees towards a possible compensation in a patent dispute case related to drug Protonix.
The Mumbai-based drugmaker said consolidated net profit fell to 3.2 billion rupees during fiscal second quarter ended September from 5.98 billion rupees a year earlier. Net sales rose 40.2 percent to 26.57 billion rupees.
Analysts had estimated the net profit at 7.68 billion rupees, according to Thomson Reuters I/B/E/S. (Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob)
Trending On Reuters
Record IPO Demand
A $75-million market debut for Indian parcel delivery firm VRL Logistics Ltd has encountered record demand, drawing bids for more than 70 times the number of shares on offer late last week, as investors bet on an e-commerce boom. Read